@article {Decramerp878, author = {Marc Decramer and Francois Maltais and Gregory Feldman and Jean Brooks and Lisa Willits and Stephanie Harris and Glenn Crater}, title = {Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD}, volume = {38}, number = {Suppl 55}, elocation-id = {p878}, year = {2011}, publisher = {European Respiratory Society}, abstract = {Introduction: GSK573719 is an inhaled LAMA with sustained 24-hour activity under development as a once-daily therapy for COPD.Objective: To evaluate the dose response of GSK573719 in patients with COPD.Methods: This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study evaluating GSK573719 administered once daily via a novel single-step activation dry powder inhaler in patients with COPD (FEV1 of >=35 and <=70\% predicted). The primary endpoint was morning pre-dose (trough) FEV1 after 28 days of treatment.Results: All doses of GSK573719 significantly increased trough FEV1 compared with placebo, with improvement ranging from 150 to 168mL (p\<0.001). All doses significantly increased 0{\textendash}6 hour weighted mean FEV1 compared with placebo with differences ranging from 113 to 211mL (p\<0.001). Additionally, all doses demonstrated significant improvements over placebo in serial FEV1 at each measured time point over 24 hours (p<=0.038). Reductions in albuterol use and improvements in FVC were also noted for all doses. All doses were well tolerated.Conclusion: Once-daily dosing with GSK573719 provides clinically significant and sustained improvement in lung function and is well tolerated over 24 hours in patients with COPD.Funded by GSK (AC4113589; NCT01030965)}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/38/Suppl_55/p878}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }